Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001833214-25-000011
Filing Date
2025-09-02
Accepted
2025-09-02 17:25:00
Documents
18

Document Format Files

Seq Description Document Type Size
1 S-3 sabs-20250902.htm S-3 534070
2 EX-5.1 sabs-ex5_1.htm EX-5.1 29343
3 EX-23.1 sabs-ex23_1.htm EX-23.1 3800
4 EX-FILING FEES sabs_exfilingfees.htm   iXBRL EX-FILING FEES 76823
5 GRAPHIC img84541401_0.jpg GRAPHIC 2898
6 GRAPHIC img84541401_1.jpg GRAPHIC 2898
7 GRAPHIC img154603834_0.jpg GRAPHIC 27850
8 GRAPHIC img154603834_1.jpg GRAPHIC 27850
  Complete submission text file 0001833214-25-000011.txt   861372

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT sabs_exfilingfees_htm.xml XML 9957
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-289992 | Film No.: 251286697
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)